Hiroshi Handa 研究室

主宰者：Hiroshi Handa

群馬大学・Gunma University Hospital

AI 要約（直近 5 年の研究成果）

要約はまだ生成されていません。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（76 件）

[2025] <scp>INTS15</scp>, A Subunit of the Integrator Complex, Plays a Key Regulatory Role in Cell Cycle and Differentiation
DOI: https://doi.org/10.1111/gtc.70015
[2025] Role of Rac1 in p53-Related Proliferation and Drug Sensitivity in Multiple Myeloma
DOI: https://doi.org/10.3390/cancers17030461
[2025] Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)
DOI: https://doi.org/10.1182/blood-2025-370
[2025] Assessment of Predictive Factors That Shorten Duration of Treatment in Patients With Multiple Myeloma Using AI: Real-World Longitudinal Study Using Data From Medical Data Vision Claims Database
DOI: https://doi.org/10.2196/75586
[2025] Clinical Significance of Lipoprotein Lipase (LPL) in People Living with HIV: A Comprehensive Assessment Including Lipidemia, Body Composition, Insulin Secretion, and Insulin Resistance
DOI: https://doi.org/10.3390/nu17203207
[2025] Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
DOI: https://doi.org/10.1038/s41408-025-01356-z
[2025] Effect of plasma exchange on tirabrutinib plasma concentration in a patient with lymphoplasmacytic lymphoma: A case report
DOI: https://doi.org/10.1007/s00280-025-04812-6
[2025] Real World Survival Outcomes of Relapsed and Refractory Multiple Myeloma Patients Receiving Second Line Therapy and Beyond in Asia
DOI: https://doi.org/10.1016/s2152-2650(25)03960-6
[2024] Genetic analysis of myeloid neoplasms with der(1;7)(q10;p10)
DOI: https://doi.org/10.1038/s41375-024-02494-2
[2024] ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone
DOI: https://doi.org/10.1182/blood.2023022540

続きを表示（残り 66 件）

[2024] Autologous <scp>HSCT</scp> with novel agent‐based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma
DOI: https://doi.org/10.1111/cas.16158
[2024] Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016–2021)
DOI: https://doi.org/10.1007/s12185-024-03754-8
[2024] Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3
DOI: https://doi.org/10.1093/jjco/hyae068
[2024] Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia
DOI: https://doi.org/10.1038/s41375-024-02296-6
[2024] Interaction between Cell Adhesion Molecule Integrin α6 and Extracellular Matrix Laminin Promotes Myeloma Progression Via Akt Signaling
DOI: https://doi.org/10.1182/blood-2024-203547
[2024] APEX1 Polymorphisms Affect Acute Myeloid Leukemia Risk, and Its Expression Is Involved in Cell Proliferation and Differentiation
DOI: https://doi.org/10.1111/ijlh.14401
[2023] [Acquired hemophilia A that developed after BNT162b2 mRNA COVID-19 vaccination and worsened following re-vaccination].
DOI: https://doi.org/10.11406/rinketsu.64.60
[2023] A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee
DOI: https://doi.org/10.1007/s12185-023-03647-2
[2023] Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
DOI: https://doi.org/10.1007/s12185-023-03686-9
[2023] Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
DOI: https://doi.org/10.1007/s12185-023-03677-w
[2023] Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT
DOI: https://doi.org/10.1007/s00277-023-05527-5
[2023] Applying Artificial Intelligence Machine Learning to Discover Factors That Shorten Duration of Treatment in Patients with Multiple Myeloma Using Real-World Patient-Level Longitudinal Data from Medical Data Vision Database
DOI: https://doi.org/10.1182/blood-2023-172849
[2023] Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms
DOI: https://doi.org/10.1182/blood-2023-185857
[2023] Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study
DOI: https://doi.org/10.1182/blood-2023-184723
[2023] PB1233 A Single-Center Study of Reduced-Dose Corticosteroids Therapy for Patients with Acquired Hemophilia A
DOI: https://doi.org/10.1016/j.rpth.2023.101047
[2023] PB0211 The Utilities of Multiple Genetic Analyses for Rare Coagulation Deficiencies and Rare Bleeding Disorders
DOI: https://doi.org/10.1016/j.rpth.2023.101283
[2023] Laparoscopic hepatectomy for hepatocellular carcinoma in patients with hemophilia A and B: a report of two cases
DOI: https://doi.org/10.1007/s12328-023-01854-2
[2023] P-274 Efficacy and safety of elranatamab in Japanese patients with relapsed/refractory multiple myeloma (RRMM): a pooled analysis from the MagnetisMM studies
DOI: https://doi.org/10.1016/s2152-2650(23)01892-x
[2023] P929: CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE
DOI: https://doi.org/10.1097/01.hs9.0000970620.26657.64
[2023] Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma
DOI: https://doi.org/10.1007/s00277-023-05212-7
[2023] Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
DOI: https://doi.org/10.1371/journal.pone.0283931
[2023] Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
DOI: https://doi.org/10.1182/bloodadvances.2022009564
[2023] Sub-lethal doses of chemotherapeutic agents induce senescence in T cells and upregulation of PD-1 expression
DOI: https://doi.org/10.1007/s10238-023-01034-z
[2023] Integrator complex subunit 15 controls mRNA splicing and is critical for eye development
DOI: https://doi.org/10.1093/hmg/ddad034
[2023] The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma
DOI: https://doi.org/10.1016/j.exphem.2023.01.006
[2023] Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression
DOI: https://doi.org/10.3390/ijms24032216
[2023] <scp>DNA</scp> damage‐induced cellular senescence is regulated by <scp>53BP1</scp> accumulation in the nuclear foci and phase separation
DOI: https://doi.org/10.1111/cpr.13398
[2023] Slowly progressing acute lymphoblastic leukemia with prolonged leukopenia
DOI: https://doi.org/10.1177/2050313x231177758
[2023] [Coagulative complete remission following early gastric cancer resection in a patient with steroid-resistant acquired hemophilia A and nephrotic syndrome].
DOI: https://doi.org/10.11406/rinketsu.64.203
[2022] Co-occurrence of relapsing polychondritis and autoimmune thyroid diseases
DOI: https://doi.org/10.1186/s13023-022-02261-5
[2022] Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial
DOI: https://doi.org/10.1007/s12185-022-03347-3
[2022] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
DOI: https://doi.org/10.1186/s12885-022-09622-0
[2022] Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
DOI: https://doi.org/10.1111/cas.15344
[2022] Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
DOI: https://doi.org/10.3791/62932
[2022] [Refractory thrombotic thrombocytopenic purpura complicated with multiple cerebral infarction].
DOI: https://doi.org/10.11406/rinketsu.63.55
[2022] Optogenetic modulation of TDP-43 phase transition accelerates ALS-related pathologies in a zebrafish model
DOI: https://doi.org/10.1254/jpssuppl.95.0_1-s13-1
[2022] Two cases of follicular lymphoma with MYC gene abnormalities that presented with bone marrow necrosis
DOI: https://doi.org/10.3960/jslrt.22004
[2022] [Spontaneous disappearance of the inhibitor during emicizumab therapy in a patient with mild hemophilia A].
DOI: https://doi.org/10.11406/rinketsu.63.1392
[2022] Clinical significance of human endogenous retrovirus K (HERV-K) in multiple myeloma progression
DOI: https://doi.org/10.1007/s12185-022-03513-7
[2022] Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)
DOI: https://doi.org/10.1182/blood-2022-168213
[2022] Application of Magnetic Nanoparticle in Cancer Surgery
DOI: https://doi.org/10.1541/ieejfms.142.236
[2022] MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression
DOI: https://doi.org/10.3390/genes14010100
[2022] P744: UNBALANCED TRANSLOCATION DER(1;7)(Q10;P10) AS A DISTINCT SUBTYPE IN MYELODYSPLASTIC SYNDROMES
DOI: https://doi.org/10.1097/01.hs9.0000845860.71732.b0
[2022] Laparoscopic hepatectomy for hepatocellular carcinoma in a patient with congenital factor V deficiency: a case report
DOI: https://doi.org/10.1186/s40792-022-01559-7
[2021] Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia
DOI: https://doi.org/10.1182/blood-2021-146744
[2021] Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms
DOI: https://doi.org/10.1182/blood-2021-149556
[2021] Reduction of blood group A antigen on erythrocytes in a patient with myelodysplastic syndrome harboring somatic mutations in RUNX1 and GATA2
DOI: https://doi.org/10.1111/trf.16766
[2021] A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival
DOI: https://doi.org/10.1111/bjh.17717
[2021] Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse
DOI: https://doi.org/10.1007/s10147-021-01991-z
[2021] An Autopsy Case of Multicentric Castleman Disease Presenting with Severe Jaundice
DOI: https://doi.org/10.2169/internalmedicine.6835-20
[2021] Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.7042
[2021] Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
DOI: https://doi.org/10.1007/s00432-021-03668-6
[2021] Expression of activated integrin β7 in multiple myeloma patients
DOI: https://doi.org/10.1007/s12185-021-03162-2
[2021] Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
DOI: https://doi.org/10.1186/s13046-021-01909-7
[2021] IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma
DOI: https://doi.org/10.1007/s10238-020-00681-w
[2021] DNA-double strand breaks enhance the expression of major histocompatibility complex class II through the ATM-NF-κΒ-IRF1-CIITA pathway
DOI: https://doi.org/10.1038/s41417-021-00302-y
[2021] Adenine nucleotide translocase 2, a putative target protein for 2-carba cyclic phosphatidic acid in microglial cells
DOI: https://doi.org/10.1016/j.cellsig.2021.109951
[2021] Pathological and molecular analysis of a composite lymphoma of mantle cell lymphoma and Epstein–Barr virus-positive follicular lymphoma
DOI: https://doi.org/10.1007/s12185-020-03035-0
[2021] Personalized treatment for multiple myeloma
[2021] [Antibody therapy for multiple myeloma].
DOI: https://doi.org/10.11406/rinketsu.62.1167
[2021] RESTORATION OF A ANTIGEN FOLLOWING AZACITIDINE TREATMENT
DOI: https://doi.org/10.3925/jjtc.67.507
[2021] Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma
DOI: https://doi.org/10.1182/blood-2021-149270
[2021] Allogeneic Stem Cell Transplantation Conditioned with Myeloablative Regimens Containing Total Body Irradiation in Adolescent and Young Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Who Were Treated with Pediatric-Type Chemotherapy
DOI: https://doi.org/10.1182/blood-2021-151855
[2021] Prognostic Impacts of Additional Cytogenetic Abnormalities Acquired at the First Relapse in Adult Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission
DOI: https://doi.org/10.1182/blood-2021-152621
[2021] The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study
DOI: https://doi.org/10.1182/blood-2021-148427
[2021] Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT
DOI: https://doi.org/10.1182/blood-2021-147587

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（76 件）

科研費（0 件）

所属学会・役職（0 件）